Zealand Pharma to Participate in Healthcare Conference
Zealand Pharma A/S is thrilled to share its upcoming involvement in the Cantor Global Healthcare Conference. The company, renowned for its innovative peptide-based medicines, is eager to highlight its commitment to enhancing healthcare solutions.
Details of the Conference
Set for an important day in September, Chief Medical Officer David Kendall, MD, will participate in a fireside chat. This event is designed to promote meaningful conversations around advancements in both healthcare and biotechnology.
Timing of the Fireside Chat
The chat will take place at 9:10 a.m. ET, a time that caters well to the interests of investors and stakeholders within the biotechnology sector. By attending the conference, Zealand Pharma will have the opportunity to connect with its audience, share valuable insights, and discuss the future of therapeutic developments.
Online Accessibility
For those who can't attend in person, Zealand Pharma will provide a live audio webcast. This approach not only reflects the company's commitment to its stakeholders but also ensures that valuable insights reach a broader audience.
How to Access the Webcast
The webcast will be accessible via the company’s official channels, making sure that important updates and discussions are available to those unable to attend. Additionally, a recording will be available after the event for future reference.
About Zealand Pharma A/S
Zealand Pharma A/S, listed on Nasdaq under the ticker ZEAL, is a leader in biotechnology innovation. With an impressive portfolio that includes over ten drug candidates currently in clinical development, the company is dedicated to pioneering peptide-based therapies.
Notable Achievements
Recently, Zealand Pharma has reached significant milestones, with two of its drug candidates already launched on the market. Furthermore, three candidates are in the late stages of development, bolstering its status as a leader in the peptide medicines field.
Investor Relations and Contact Information
Zealand Pharma fosters strong connections within the pharmaceutical community and prioritizes establishing valuable partnerships for the development and commercialization of its products. Investors seeking information or insight into the company's direction can reach out directly.
Contact Details
For inquiries related to investor relations, Adam Lange, the Investor Relations Officer at Zealand Pharma, can assist. In addition, Anna Krassowska, PhD, serves as the Vice President of Investor Relations and Corporate Communications, addressing both investor and media needs.
Frequently Asked Questions
What does Zealand Pharma focus on?
Zealand Pharma is dedicated to discovering and developing peptide-based medicines that aim to improve therapeutic options across various medical fields.
Who will represent Zealand Pharma at the event?
David Kendall, MD, the Chief Medical Officer, will be the representative from Zealand Pharma participating in the fireside chat at the conference.
How can I watch the live webcast?
You can access the live webcast on Zealand Pharma's official website, and it will also be archived for anyone who cannot attend the live event.
What are Zealand Pharma's key achievements?
Zealand Pharma has positioned more than ten drug candidates in clinical development, and it has already brought notable products to the market.
Who should I reach out to for inquiries about investor relations?
Adam Lange is your point of contact for any investor relations questions. For broader communications, you can also reach out to Anna Krassowska.
